Germany – Still Europe's Stand-Out Medtech Innovation Market
Executive Summary
Germany's introduction of benefit assessments for class IIb and class III medical devices, and the impending EU Medical Device and IVD Regulations will place an unquantified strain on medtech manufacturers in Europe's largest market. But new innovation schemes are adding more dimensions for businesses locally.
You may also be interested in...
Germany's New High-Risk Assessment Medtech Scheme Off To Slow Start
Germany's new testing and treatment methods (NUBs) scheme for assessing benefit in high-risk products for inpatient use recently processed its first batch of applications. But, as with its longer-established outpatient products counterpart, it does not seem to be an instant success, says German reimbursement expert Ben Modley.
Industry Sees Much To Improve In Germany's New High-Risk Medtech Assessment Scheme
Only two of eight treatments passed muster under Germany's new NUBs scheme for assessing the benefit of high-risk products for inpatient use. As with the country's outpatient assessment counterpart, industry is pushing for changes.
Meetings Set To Address EU Delegated & Implementing Acts
With the EU’s new medtech regulations due to enter into force in as little as four months’ time, meetings have been set on the European Commission calendar to start addressing the crucial "delegated and implementing acts" for making the changes a reality. Also, an overview of the 2017 calendar for key EU medtech policymaking bodies.